A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis

• Main Authors: Chan, Wah Kheong, Nik Mustapha, Nik Raihan, Mahadeva, Sanjiv
• Format: Article
• Published: Elsevier 2017
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/22840/; https://doi.org/10.1016/j.cgh.2017.04.016

Background & Aims Silymarin is a complex mixture of 6 major flavonolignans and other minor polyphenolic compounds derived from the milk thistle plant Silybum marianum; it has shown antioxidant, anti-inflammatory and antifibrotic effects, and may be useful in patients with nonalcoholic fatty liver disease (NAFLD). We aimed to study the efficacy of silymarin in patients with nonalcoholic steatohepatitis (NASH)—the more severe form of NAFLD. Methods We performed a randomized, double-blind, placebo-controlled trial of consecutive adults with biopsy-proven NASH and a NAFLD activity score (NAS) of 4 or more at a tertiary care hospital in Kuala Lumpur, Malaysia, from November 2012 through August 2014. Patients were randomly assigned to groups given silymarin (700 mg; n = 49 patients) or placebo (n = 50 patients) 3 times daily for 48 weeks. After this 48-week period, liver biopsies were repeated. The primary efficacy outcome was a decrease of 30% or more in NAS; findings from 48-week liver biopsies were compared with those from the baseline biopsy. Secondary outcomes included changes in steatosis, lobular inflammation, hepatocyte ballooning, NAS and fibrosis score, and anthropometric measurements, as well as glycemic, lipid, and liver profiles and liver stiffness measurements. Results The percentage of patients achieving the primary efficacy outcome did not differ significantly between the groups (32.7% in the silymarin group vs 26.0% in the placebo group; P =.467). A significantly higher proportion of patients in the silymarin group had reductions in fibrosis based on histology (reductions of 1 point or more; 22.4%) than did the placebo group (6.0%; P =.023), and based on liver stiffness measurements (decrease of 30% or more; 24.2%) than did the placebo group (2.3%; P =.002). The silymarin group also had significant reductions in mean aspartate aminotransferase to platelet ratio index (reduction of 0.14, P =.011 compared with baseline), fibrosis-4 score (reduction of 0.20, P =.041 compared with baseline), and NAFLD fibrosis score (reduction of 0.30, P <.001 compared with baseline); these changes were not observed in the placebo group (reduction of 0.07, P =.154; increase of 0.18, P =.389; and reduction of 0.05, P =.845, respectively). There was no significant difference between groups in number of adverse events; adverse events that occurred were not attributed to silymarin. Conclusions In a randomized trial of 99 patients, we found that silymarin (700 mg, given 3 times daily for 48 weeks) did not reduce NAS scores by 30% or more in a significantly larger proportion of patients with NASH than placebo. Silymarin may reduce liver fibrosis but this remains to be confirmed in a larger trial. It appears to be safe and well tolerated. ClinicalTrials.gov: NCT02006498.